Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Company's cash runway extended into 2026, with a net loss of $24.0 million for Q3 2023

Related Keywords

Alexc Sapir , ,Fulcrum Therapeutics Inc ,Iopharmaceutical Company ,Sulc ,Sickle Cell Disease ,Cash Equivalents ,Facioscapulohumeral Muscular Dystrophy ,Fulcrum Therapeutics ,E3 2022 ,Clinical Development ,Cash Position ,Marketable Securities ,